Top-Rated StocksTop-RatedNASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis $66.43 +1.29 (+1.98%) Closing price 09/30/2025 04:00 PM EasternExtended Trading$66.43 0.00 (0.00%) As of 09/30/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Protagonist Therapeutics Stock (NASDAQ:PTGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PTGX alerts:Sign Up Key Stats Today's Range$65.06▼$67.0450-Day Range$50.96▼$67.4252-Week Range$33.31▼$68.26Volume1.45 million shsAverage Volume1.17 million shsMarket Capitalization$4.13 billionP/E Ratio94.90Dividend YieldN/APrice Target$68.36Consensus RatingBuy Company Overview Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care. Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease. PTG-200, a selective interleukin-23 receptor antagonist, is in Phase 2 clinical trials for moderate to severe Crohn’s disease. The company’s PTG-300 program is a hepcidin mimetic being evaluated in hematologic disorders characterized by iron overload, including polycythemia vera and myelofibrosis. Founded in 2006 and headquartered in San Diego, California, Protagonist Therapeutics conducts global clinical trials across North America, Europe and Asia. The company is led by a team of seasoned biotechnology executives with deep expertise in peptide drug discovery and development. Protagonist maintains collaborations with academic institutions and industry partners to advance its pipeline and explore additional therapeutic areas where oral peptide therapeutics may deliver significant patient benefit.AI Generated. May Contain Errors. Read More Protagonist Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScorePTGX MarketRank™: Protagonist Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 759th out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.7 / 5Analyst RatingBuy Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Upside/DownsideThe consensus price target for Protagonist Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageProtagonist Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Protagonist Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from $2.43 to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is 94.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 282.59.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is 94.90, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 76.58.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 5.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Protagonist Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.71% of the outstanding shares of Protagonist Therapeutics have been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Protagonist Therapeutics has recently decreased by 2.77%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.71% of the outstanding shares of Protagonist Therapeutics have been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Protagonist Therapeutics has recently decreased by 2.77%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment0.81 News SentimentProtagonist Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Protagonist Therapeutics this week, compared to 7 articles on an average week.MarketBeat Follows1 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,944,577.00 in company stock.Percentage Held by InsidersOnly 4.90% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Protagonist Therapeutics' insider trading history. Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTGX Stock News HeadlinesProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $68.08 Average Target Price from AnalystsSeptember 25, 2025 | americanbankingnews.comBarclays Initiates Coverage of Protagonist Therapeutics (PTGX) with Overweight RecommendationSeptember 17, 2025 | msn.comBuy this stock tomorrowFamed futurist Eric Fry just unveiled his “Sell This, Buy That” strategy — including 7 free trade ideas like a small robotics firm he calls an “upgrade to Tesla,” already sitting on a $23 billion backlog. | InvestorPlace (Ad)Demystifying Protagonist Therapeutics: Insights From 4 Analyst ReviewsSeptember 17, 2025 | benzinga.comProtagonist Therapeutics, Inc. (PTGX): A Bull Case TheorySeptember 17, 2025 | msn.comProtagonist Therapeutics, Inc. (PTGX): A Bull Case Theory September 17, 2025 | insidermonkey.comBarclays backs biotech with fresh calls on oncology and immunology stocksSeptember 17, 2025 | investing.comProtagonist Therapeutics initiated with an Overweight at BarclaysSeptember 16, 2025 | msn.comSee More Headlines PTGX Stock Analysis - Frequently Asked Questions How have PTGX shares performed this year? Protagonist Therapeutics' stock was trading at $38.60 at the beginning of 2025. Since then, PTGX shares have increased by 72.1% and is now trading at $66.43. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) released its earnings results on Wednesday, August, 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $0.02. The company had revenue of $5.55 million for the quarter, compared to the consensus estimate of $8.32 million. Protagonist Therapeutics had a trailing twelve-month return on equity of 8.12% and a net margin of 24.88%. When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AU Optronics (AUOTY). Company Calendar Last Earnings8/06/2025Today9/30/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTGX CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees120Year Founded2006Price Target and Rating Average Price Target for Protagonist Therapeutics$68.36 High Price Target$80.00 Low Price Target$38.00 Potential Upside/Downside+2.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$0.70 Trailing P/E Ratio94.90 Forward P/E Ratio27.34 P/E GrowthN/ANet Income$275.19 million Net Margins24.88% Pretax Margin25.71% Return on Equity8.12% Return on Assets7.41% Debt Debt-to-Equity RatioN/A Current Ratio16.97 Quick Ratio16.97 Sales & Book Value Annual Sales$434.43 million Price / Sales9.51 Cash Flow$4.61 per share Price / Cash Flow14.42 Book Value$11.33 per share Price / Book5.86Miscellaneous Outstanding Shares62,210,000Free Float59,163,000Market Cap$4.13 billion OptionableOptionable Beta2.22 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:PTGX) was last updated on 10/1/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondMost “hot AI stocks” will vanish — but Weiss Ratings’ system, ranked #1 for accuracy, just flagged 10 AI stock...Weiss Ratings | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThe 5th financial revolution is bigger than AIBacktests show this revolutionary technology could have transformed the 10 worst S&P stocks into winners. Turn...TradeSmith | SponsoredTrump is Fast-Tracking These Three CompaniesThe Trump administration is planning to invest DIRECTLY in a small sector of the stock market… And they just r...InvestorPlace | SponsoredThe same playbook as Apple, Amazon, and Nvidia?Alexander Green has found a tiny stock following the same playbook that made Apple, Amazon, and Nvidia househo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.